Technology area: Biotechnology & Pharmaceuticals
7 pending office actions • 1 client • 6 examiners • 4 art units • 0 of 7 (0%) have an AI response strategy ready • 3 patents granted in the last 365 days
K&L Gates LLP - Tessera has 7 pending office actions in Biotechnology & Pharmaceuticals. The associated record lists 34332 career applications, an 84.49% resolved allowance rate, and 3.82 average office actions per allowance. The profile links a focused current workload to a broad historical application record.
The allowance rate and office-action average describe resolved activity and should not be used as a direct prediction for pending Tessera matters. They do indicate that allowance has involved multiple examination interactions in the recorded portfolio. Practitioners should build responses around the particular biological or pharmaceutical distinctions, disclosure support, and rejection grounds in each case.
Based on the USPTO statutory response window for each pending office action. 5 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Every pending office action with a known statutory deadline, placed on a days-until-due axis. Dots left of Today are overdue; the further right, the more runway. Cases that share a deadline window stack vertically. 5 of the docket's apps have a known mailing date.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 2 (29%) |
| §112 only | 2 (29%) |
| Double-patenting + other | 1 (14%) |
| Multi-statute (no §101) | 2 (29%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| LEITH, NANCY J | 2 | 74.7% | +44.0% |
| PERSONS, JENNA L | 1 | 50.8% | +61.7% |
| ZARA, JANE J | 1 | 71.0% | +16.1% |
| LEE, JAE W | 1 | 65.6% | +38.5% |
| KONOPKA, CATHERINE ANNE | 1 | 57.5% | +66.2% |
| MCLEOD, AFRICA MHAIRIE | 1 | 52.8% | +67.7% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17929124 | METHODS AND COMPOSITIONS FOR MODULATING A GENOME | LEE, JAE W | 6d |
| 18061632 | TEMPLATE GUIDE RNA MOLECULES | ZARA, JANE J | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 7 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 19272711 | METHODS AND COMPOSITIONS FOR MODULATING A GENOME | LEITH, NANCY J | 89d overdue |
| 19272775 | METHODS AND COMPOSITIONS FOR MODULATING A GENOME | LEITH, NANCY J | 86d overdue |
| 18469344 | SERPINA-MODULATING COMPOSITIONS AND METHODS | PERSONS, JENNA L | 49d overdue |
| 17929124 | METHODS AND COMPOSITIONS FOR MODULATING A GENOME | LEE, JAE W | 6d |
| 17577942 | RECOMBINASE COMPOSITIONS AND METHODS OF USE | MCLEOD, AFRICA MHAIRIE | 21d |
| 18061632 | TEMPLATE GUIDE RNA MOLECULES | ZARA, JANE J | — |
| 17823726 | HOST DEFENSE SUPPRESSING METHODS AND COMPOSITIONS FOR MODULATING A GENOME | KONOPKA, CATHERINE ANNE | — |
| Client (Assignee) | Pending OAs |
|---|---|
| Flagship Pioneering | 7 |
| Art Unit | Apps |
|---|---|
| 1636 | 2 |
| 1637 | 2 |
| 1635 | 2 |
| 1656 | 1 |
| App # | Title | Client | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|---|
| 19272711 | METHODS AND COMPOSITIONS FOR MODULATING A GENOME | Flagship Pioneering Innovations Vi, LLC | LEITH, NANCY J | 1636 | §103Other | Final Rejection | 89d overdue | Pending | Jul 17, 2025 |
| 19272775 | METHODS AND COMPOSITIONS FOR MODULATING A GENOME | Flagship Pioneering Innovations Vi, LLC | LEITH, NANCY J | 1636 | §103Other | Final Rejection | 86d overdue | Pending | Jul 17, 2025 |
| 18469344 | SERPINA-MODULATING COMPOSITIONS AND METHODS | Flagship Pioneering Innovations Vi, LLC | PERSONS, JENNA L | 1637 | §103§112DP | Non-Final OA | 49d overdue | Pending | Sep 18, 2023 |
| 18061632 | TEMPLATE GUIDE RNA MOLECULES | Flagship Pioneering Innovations Vi, LLC | ZARA, JANE J | 1637 | §102§103§112 | Non-Final OA | — | Pending | Dec 05, 2022 |
| 17929124 | METHODS AND COMPOSITIONS FOR MODULATING A GENOME | Flagship Pioneering Innovations Vi, LLC | LEE, JAE W | 1656 | §103§112 | Final Rejection | 6d | Pending | Sep 01, 2022 |
| 17823726 | HOST DEFENSE SUPPRESSING METHODS AND COMPOSITIONS FOR MODULATING A GENOME | Flagship Pioneering Innovations Vi, LLC | KONOPKA, CATHERINE ANNE | 1635 | §112Other | Final Rejection | — | Pending | Aug 31, 2022 |
| 17577942 | RECOMBINASE COMPOSITIONS AND METHODS OF USE | Flagship Pioneering Innovations Vi, LLC | MCLEOD, AFRICA MHAIRIE | 1635 | §112 | Final Rejection | 21d | Pending | Jan 18, 2022 |
IP Author helps law firms respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial84.5% of resolved applications prosecuted by K&L Gates LLP - Tessera were allowed, across 34,332 applications in USPTO records.
3.82 office actions per allowed application on average.
7 pending office actions as of October 2026, for 1 client, before 6 examiners in 4 art units.
